- Conditions
- Breast Cancer
- Interventions
- PET/MR
- Diagnostic Test
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,429
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 38
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Prostatic Neoplasms
- Interventions
- G-202
- Drug
- Lead sponsor
- GenSpera, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- APL-1202 in combination with tislelizumab, Tislelizumab alone
- Drug
- Lead sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer of the Breast
- Interventions
- Omeprazole
- Drug
- Lead sponsor
- Kathy Miller
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Carmel, Indiana • Indianapolis, Indiana + 3 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Erlotinib, Erlotinib plus sulindac, Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, Leuprolide, Dutasteride
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Pancreatic Cancer
- Interventions
- Paricalcitol
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
- Interventions
- Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
- Conditions
- Melanoma, Melanoma Stage III
- Interventions
- PET Scan, Nivolumab, Ipilimumab, Surgical Resection of Melanoma
- Diagnostic Test · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
- Conditions
- Lung Cancer
- Interventions
- Gemcitabine, Pemetrexed, Surgery
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Cancer
- Interventions
- PF-07220060, letrozole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
- Interventions
- Multidisciplinary Prehabilitation Program
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Atorvastatin, Capecitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Breast Carcinoma
- Interventions
- Behavioral Dietary Intervention
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Kansas City, Missouri • New York, New York • Nashville, Tennessee
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
- Interventions
- Durvalumab, Carboplatin, Nab-paclitaxel, Cisplatin, Surgical resection, IMRT
- Drug · Procedure · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, leucovorin calcium, fluorouracil, nelfinavir mesylate, stereotactic body radiation therapy, hypofractionated radiation therapy, therapeutic conventional surgery
- Drug · Radiation · Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Palbociclib, Goserelin, Oncotype DX Breast Recurrence Score
- Drug · Diagnostic Test
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Foscarnet sodium, Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • St Louis, Missouri + 3 more
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, carboplatin, docetaxel
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Pomona, California
- Conditions
- Pancreatic Cancer
- Interventions
- PLDR
- Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania